CompletedInterventionalPhase 1Updated Oct 20, 2014
Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide | NCT00044707 | Trialant
CompletedInterventionalPhase 2Updated May 21, 2015
Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide
ClinicalTrials.gov ID
NCT00044707
Lead Sponsor
AstraZenecaINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 2
Enrollment
24Actual
Last Update Posted
May 21, 2015Estimated
Start Date
Aug 2002
Primary Completion Date
Sep 2002Actual
Completion Date
Sep 2002Actual
Brief Summary
This is a randomized, single-blind, placebo-controlled, crossover study to examine the effect of pramlintide on the pharmacokinetics of an orally administered medication
Diabetes Mellitus, Non-Insulin-Dependent
Pramlintide acetate
Ages Eligible for Study
Adult (18-64)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Type 2 diabetes mellitus treated with diet and/or oral agents